Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allergenic extract of birch is a biologic immunotherapy derived from the pollen of birch trees (Betula species). It is used to treat allergic rhinitis and/or rhinoconjunctivitis, and in some cases mild asthma, caused by pollen from birch and related trees in the Betulaceae family, such as alder and hazel. [3] The active components are birch pollen allergens which desensitize the patient's immune system through repeated exposure. This process aims to reduce the IgE-mediated allergic response that triggers symptoms. [6, 24] Treatment, which typically begins weeks or months before the pollen season, is administered via subcutaneous injection or sublingually as liquid drops or tablets. [1, 22, 26] Various formulations exist, including standardized extracts, non-standardized extracts, and chemically modified extracts (allergoids) designed to reduce allergenicity. [14, 19]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allergenic extract of birch.